Year Final Analysis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Year Final Analysis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Year Final Analysis Today - Breaking & Trending Today

Ruxolitinib Shows Sustained Efficacy Over Best Available Therapy in Steroid-Refractory/Dependent cGVHD

Published: December 11, 2023

Treatment with ruxolitinib led to prolonged failure-free survival and improved disease control vs best available treatment in patients with either steroid-refractory or -dependent chronic graft-vs-host disease.

Source: onclive.com

Related Topics:

Robert ZeiserCenter At University Of FreiburgMedical CenterPatients With Chronic Graft Versus Host DiseaseYear Final AnalysisSafety FromSteroid Refractory Dependent GvhdPhase 3 Reach3 Trial Nct03112603